Refine
Year of publication
Document Type
- Article (51)
- Postprint (28)
- Conference Proceeding (3)
- Other (1)
- Preprint (1)
Keywords
- inflammation (7)
- NASH (6)
- oxidative stress (6)
- cell-based assay (5)
- NAFLD (4)
- cholesterol (4)
- insulin (3)
- type 2 diabetes (3)
- Akt pathway (2)
- BoNT (2)
- BoNT/B uptake (2)
- Botulinum neurotoxin (2)
- CRISPR editing validation (2)
- E-2 (2)
- FGF21 (2)
- Glucagon (2)
- IL-8 transcription (2)
- M1/M2 differentiation (2)
- NAFLD/MAFLD (2)
- PUFA (2)
- RRR (2)
- TLR signaling (2)
- VGCC (2)
- accumulation (2)
- botulinum toxin (2)
- cancer cachexia (2)
- cell-based in vitro assay (2)
- copy number analyses (2)
- cyclooxygenase (2)
- disease (2)
- eicosanoids (2)
- endurance exercise (2)
- erythropoiesis (2)
- expression (2)
- genetically modified BoNT (2)
- glucose (2)
- glucose intolerance (2)
- hepatic steatosis (2)
- homologous recombination deficiency (2)
- homology-directed repair (2)
- induced pluripotent stem cells (2)
- insulin-resistance (2)
- interleukin-8 (2)
- kupffer cells (2)
- lipid peroxidation (2)
- macrophages (2)
- mice lacking (2)
- motor neurons (2)
- muscarinic acetylcholine receptor (2)
- neurotoxins (2)
- non-alcoholic fatty liver disease (NAFLD) (2)
- nonalcoholic steatohepatthis (2)
- obesity (2)
- polyenoic fatty acids (2)
- rat hepatocytes (2)
- replacement (2)
- suppress VLDL secretion (2)
- tetanus toxin (2)
- vicious cycle (2)
- voltage-dependent calcium channels (2)
- white adipose tissue (2)
- Allantoin (1)
- Anaphylatoxin (1)
- Anatomy (1)
- Animal (1)
- Aryl-hydrocarbon receptor (1)
- Biochemical analysis (1)
- Botulinum toxin (1)
- Catecholamine (1)
- Complement system (1)
- Confluence (1)
- Cyp2b1 (1)
- Dietary Cholesterol (1)
- Endocrine disruption (1)
- Epigenetics (1)
- Experimental study (1)
- Exploration (1)
- FTY720 (1)
- Fetal programming (1)
- Hepatic artery (1)
- Hepatic glucose balance (1)
- Hepatic hemodynamics (1)
- Hepatic lactate balance (1)
- Hepatic nerve (1)
- Hepatocyte (rat) (1)
- IB (1)
- Inflammation (1)
- Insulin signalling (1)
- IκB (1)
- Kupffer Cells (1)
- Molecular cloning and expression (1)
- Monocyte (1)
- NF-?B (1)
- NF-B (1)
- NF-κB (1)
- Non-alcoholic fatty liver disease (1)
- Nonalcoholic Fatty Liver Disease (NAFLD) (1)
- Nonalcoholic Steatohepatitis (NASH) (1)
- PGC1 alpha (1)
- Palmitate (1)
- Perfusion (1)
- Phosphoenolpyruvate carboxykinase (1)
- Portal vein (1)
- Prostaglandin E₂ (1)
- Prostaglandin receptor (1)
- Prostaglandin receptor EP4 (1)
- Rat (1)
- S1P receptors (1)
- SLC13A5 (1)
- Signal transduction (1)
- Sphingolipids (1)
- Sphingosine 1-phosphate (1)
- Technique (1)
- Thyroid hormone (1)
- Tumor necrosis factor alpha (1)
- Typical Western Diet (1)
- UDP-glucuronosyltransferase (1)
- Urate (1)
- Xenobesity (1)
- activation (1)
- adenylate-cyclase (1)
- aggregated immunoglobulin-g (1)
- arachidonic-acid (1)
- assessment (1)
- complement (1)
- constitutive androstane receptor (1)
- cytokine (1)
- cytokines (1)
- eNOS (1)
- enzyme induction (1)
- fatty liver (1)
- flow (1)
- intercellular communication (1)
- lactate output (1)
- liver toxicity (1)
- mPGES (1)
- mRNA degradation (1)
- macrophage (1)
- metabolic syndrome (1)
- metabolism (1)
- mixtures (1)
- mouse lethality assay (1)
- perfused-rat-liver (1)
- potency (1)
- potency assessment (1)
- pregnane X-receptor (1)
- prostaglandin E-2 (1)
- prostaglandin E2 (1)
- prostaglandin receptor (1)
- prostaglandin-f2-alpha (1)
- signal transduction (1)
- suppressor of cytokine signaling (SOCS) (1)
- triazole fungicides (1)
- type 2 diabetes (T2DM) (1)
- type II diabetes (T2DM) (1)
Prostaglandins, released from Kupffer cells, have been shown to mediate the increase in hepatic glycogenolysis by various stimuli such as zymosan, endotoxin, immune complexes, and anaphylotoxin C3a involving prostaglandin (PG) receptors coupled to phospholipase C via a G(0) protein. PGs also decreased glucagon-stimulated glycogenolysis in hepatocytes by a different signal chain involving PGE(2) receptors coupled to adenylate cyclase via a G(i) protein (EP(3) receptors). The source of the prostaglandins for this latter glucagon-antagonistic action is so far unknown. This study provides evidence that Kupffer cells may be one source: in Kupffer cells, maintained in primary culture for 72 hours, glucagon (0.1 to 10 nmol/ L) increased PGE(2), PGF(2 alpha), and PGD(2) synthesis rapidly and transiently. Maximal prostaglandin concentrations were reached after 5 minutes. Glucagon (1 nmol/L) elevated the cyclic adenosine monophosphate (cAMP) and inositol triphosphate (InsP(3)) levels in Kupffer cells about fivefold and twofold, respectively. The increase in glyco gen phosphorylase activity elicited by 1 nmol/L glucagon was about twice as large in monocultures of hepatocytes than in cocultures of hepatocytes and Kupffer cells with the same hepatocyte density. Treatment of cocultures with 500 mu mol/L acetylsalicylic acid (ASA) to irreversibly inhibit cyclooxygenase (PGH-synthase) 30 minutes before addition of glucagon abolished this difference. These data support the hypothesis that PGs produced by Kupffer cells in response to glucagon might participate in a feedback loop inhibiting glucagon-stimulated glycogenolysis in hepatocytes.